Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Orano Med LLC
Cellectar Biosciences, Inc.
Degron Therapeutics Co.
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Sumitomo Pharma America, Inc.
SCRI Development Innovations, LLC
Nuvation Bio Inc.
Quadriga Biosciences, Inc.
Celgene
Celgene
Tocagen Inc.
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Pfizer
Case Comprehensive Cancer Center
Neotropix
Pharmacyclics LLC.